{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:51:07Z","timestamp":1777377067026,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.vascn.2021.107125","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T11:57:44Z","timestamp":1630929464000},"page":"107125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Reliable identification of cardiac conduction abnormalities in drug discovery using automated patch clamp II: Best practices for Nav1.5 peak current in a high throughput screening environment"],"prefix":"10.1016","volume":"112","author":[{"given":"Maria Giustina","family":"Rotordam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Obergrussberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Brinkwirth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Takasuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e1s","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom A.","family":"Goetze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Rapedius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatsue","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Fertig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Stoelzle-Feix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.vascn.2021.107125_bb0005","first-page":"79","article-title":"The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis","volume":"17","author":"Antzelevitch","year":"2006","journal-title":"Journal of Cardiovascular Electrophysiology"},{"issue":"5","key":"10.1016\/j.vascn.2021.107125_bb0010","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1085\/jgp.81.5.613","article-title":"Lidocaine block of cardiac sodium channels","volume":"81","author":"Bean","year":"1983","journal-title":"The Journal of General Physiology"},{"issue":"1","key":"10.1016\/j.vascn.2021.107125_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/cpph.70","article-title":"Automated dynamic clamp for simulation of IK1 in human induced pluripotent stem cell-derived cardiomyocytes in real time using patchliner dynamite8","volume":"88","author":"Becker","year":"2020","journal-title":"Current Protocols in Pharmacology"},{"issue":"1","key":"10.1016\/j.vascn.2021.107125_bb0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/jpet.112.198887","article-title":"A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias","volume":"344","author":"Belardinelli","year":"2013","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"19","key":"10.1016\/j.vascn.2021.107125_bb0025","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1111\/bph.13940","article-title":"Predicting QRS and PR interval prolongations in humans using nonclinical data","volume":"174","author":"Bergenholm","year":"2017","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2021.107125_bb0030","doi-asserted-by":"crossref","first-page":"106884","DOI":"10.1016\/j.vascn.2020.106884","article-title":"Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment","volume":"105","author":"Brinkwirth","year":"2020","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2021.107125_bb0035","series-title":"Methods in molecular biology, potassium channels","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-59745-526-8_13","article-title":"Planar patch clamp: Advances in electrophysiology","volume":"Vol. 491","author":"Br\u00fcggemann","year":"2008"},{"key":"10.1016\/j.vascn.2021.107125_bb0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.vascn.2016.05.012","article-title":"Comprehensive in vitro Proarrhythmia assay (CiPA): Pending issues for successful validation and implementation","volume":"81","author":"Cavero","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2021.107125_bb0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s002329900083","article-title":"Sea anemone toxin (ATX II) modulation of heart and skeletal muscle sodium channel \u03b1-subunits expressed in tsA201 cells","volume":"152","author":"Chahine","year":"1996","journal-title":"The Journal of Membrane Biology"},{"key":"10.1016\/j.vascn.2021.107125_bb0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.12688\/f1000research.5544.1","article-title":"Late cardiac sodium current can be assessed using automated patch-clamp","volume":"3","author":"Chevalier","year":"2014","journal-title":"F1000Research"},{"issue":"10","key":"10.1016\/j.vascn.2021.107125_bb0055","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004370","article-title":"Ranolazine for congenital long QT syndrome type III (LQT3): Experimental and long-term clinical data","volume":"9","author":"Chorin","year":"2016","journal-title":"Circulation. Arrhythmia and Electrophysiology"},{"key":"10.1016\/j.vascn.2021.107125_bb0060","unstructured":"CiPA Compounds as of May 10, 2016. (n.d.). Retrieved July 9, 2021, from https:\/\/cipaproject.org\/wp-content\/uploads\/2016\/05\/CiPA-Compounds.pdf."},{"issue":"2","key":"10.1016\/j.vascn.2021.107125_bb0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.vascn.2009.04.059","article-title":"Translation between in vitro inhibition of the cardiac Nav1.5 channel and pre-clinical and clinical QRS widening","volume":"60","author":"Cordes","year":"2009","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2021.107125_bb0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel","volume":"81","author":"Crumb","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2021.107125_bb0075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fphar.2014.00203","article-title":"Early identification of hERG liability in drug discovery programs by automated patch clamp","volume":"5","author":"Danker","year":"2014","journal-title":"Frontiers in Pharmacology"},{"issue":"20","key":"10.1016\/j.vascn.2021.107125_bb0080","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1001\/jama.1993.03510200057032","article-title":"Mortality following ventricular arrhythmia suppression by encainide, after cardiac arrhythmia suppression trial","volume":"270","author":"Epstein","year":"1993","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vascn.2021.107125_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1087057115594589","article-title":"A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm","volume":"21","author":"Fermini","year":"2016","journal-title":"Journal of Biomolecular Screening"},{"issue":"2","key":"10.1016\/j.vascn.2021.107125_bb0090","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1124\/mol.106.023473","article-title":"State-dependent verapamil block of the cloned human Cav3.1 T-type Ca2+ channel","volume":"70","author":"Freeze","year":"2006","journal-title":"Molecular Pharmacology"},{"issue":"7","key":"10.1016\/j.vascn.2021.107125_bb0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd.2015.34","article-title":"Evolution of strategies to improve preclinical cardiac safety testing","volume":"15","author":"Gintant","year":"2016","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.vascn.2021.107125_bb0100","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3389\/fphys.2017.01094","article-title":"A hybrid model for safety pharmacology on an automated patch clamp platform: Using dynamic clamp to join iPSC-derived cardiomyocytes and simulations of Ik1 ion channels in real-time","volume":"8","author":"Goversen","year":"2018","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.vascn.2021.107125_bb0105","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1177\/1535370218777972","article-title":"Dysfunctional Nav1.5 channels due to SCN5A mutations","volume":"243","author":"Han","year":"2018","journal-title":"Experimental Biology and Medicine"},{"key":"10.1016\/j.vascn.2021.107125_bb0110","doi-asserted-by":"crossref","first-page":"106890","DOI":"10.1016\/j.vascn.2020.106890","article-title":"A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: An illustrative example using the CiPA model","volume":"105","author":"Han","year":"2020","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2021.107125_bb0115","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1476-5381.2011.01415.x","article-title":"On the relationship between block of the cardiac Na+ channel and drug-induced prolongation of the QRS complex","volume":"164","author":"Harmer","year":"2011","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2021.107125_bb0120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yjmcc.2013.08.010","article-title":"Dynamics of the late Na+ current during cardiac action potential and its contribution to afterdepolarizations","volume":"64","author":"Horvath","year":"2013","journal-title":"Journal of Cell Cardiology"},{"issue":"4","key":"10.1016\/j.vascn.2021.107125_bb0130","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuroscience.2006.07.010","article-title":"Temperature dependence of T-type calcium channel gating","volume":"142","author":"Iftinca","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.vascn.2021.107125_bb0135","series-title":"Assay guidance manual","article-title":"HTS assay validation 2. Stability and process studies","author":"Iversen","year":"2012"},{"issue":"5","key":"10.1016\/j.vascn.2021.107125_bb0140","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/clpt.2014.155","article-title":"Differentiating drug-induced multichannel block on the electrocardiogram: Randomized study of dofetilide, quinidine, ranolazine, and verapamil","volume":"96","author":"Johannesen","year":"2014","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"10.1016\/j.vascn.2021.107125_bb0145","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vascn.2004.06.003","article-title":"Variability in the measurement of hERG potassium channel inhibition: Effects of temperature and stimulus pattern","volume":"50","author":"Kirsch","year":"2004","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"3\u20134","key":"10.1016\/j.vascn.2021.107125_bb0150","first-page":"84","article-title":"Temperature effects on non-TRP Ion channels and neuronal excitability","volume":"3","author":"Korogod","year":"2017","journal-title":"Opera Medica Et Physiologica"},{"key":"10.1016\/j.vascn.2021.107125_bb0155","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1038\/s41598-020-62344-w","article-title":"Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells","volume":"10","author":"Kramer","year":"2020","journal-title":"Nature Scientific Reports"},{"key":"10.1016\/j.vascn.2021.107125_bb0160","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/srep02100","article-title":"MICE models: Superior to the HERG model in predicting torsade de pointes","volume":"3","author":"Kramer","year":"2013","journal-title":"Scientific Reports"},{"key":"10.1016\/j.vascn.2021.107125_bb0165","article-title":"Applying automated patch-clamp to disease modeling\u202f: Recapitulate phenotypes of Brugada syndrome using iPSC-CMs","author":"Li","year":"2021","journal-title":"Biorvix, pre-print."},{"key":"10.1016\/j.vascn.2021.107125_bb0170","doi-asserted-by":"crossref","first-page":"592893","DOI":"10.3389\/fcell.2020.592893","article-title":"Disease phenotypes and mechanisms of iPSC-derived cardiomyocytes from brugada syndrome patients with a loss-of-function SCN5A mutation","volume":"8","author":"Li","year":"2020","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"2","key":"10.1016\/j.vascn.2021.107125_bb0175","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/cpt.1184","article-title":"Assessment of an in silico mechanistic model for proarrhythmia risk prediction under the CiPA initiative","volume":"105","author":"Li","year":"2019","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"5","key":"10.1016\/j.vascn.2021.107125_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2020.08.003","article-title":"Reengineering an antiarrhythmic drug using patient hiPSC cardiomyocytes to improve therapeutic potential and reduce toxicity","volume":"27","author":"McKeithan","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.vascn.2021.107125_bb0185","series-title":"Ion channels: Methods and protocols, methods in molecular biology","first-page":"171","article-title":"Automated planar patch-clamp","volume":"Vol. 998","author":"Milligan","year":"2013"},{"issue":"1","key":"10.1016\/j.vascn.2021.107125_bb0190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/PL00004921","article-title":"Kinetics and state-dependent effects of verapamil on cardiac L-type calcium channels","volume":"355","author":"Nawrath","year":"1996","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"issue":"4","key":"10.1016\/j.vascn.2021.107125_bb0195","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1152\/ajpheart.00243.2011","article-title":"Mechanisms of atrial-selective block of Na + channels by ranolazine: II. Insights from a mathematical model","volume":"301","author":"Nesterenko","year":"2011","journal-title":"American Journal of Physiology - Heart and Circulatory Physiology"},{"issue":"3","key":"10.1016\/j.vascn.2021.107125_bb0200","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/17460441.2018.1428555","article-title":"An update on the advancing high-throughput screening techniques for patch clamp-based ion channel screens: Implications for drug discovery","volume":"13","author":"Obergrussberger","year":"2018","journal-title":"Expert Opinion on Drug Discovery"},{"key":"10.1016\/j.vascn.2021.107125_bb0205","article-title":"Automated patch clamp analysis of nACh\u03b17 and NaV 1.7 channels","volume":"65","author":"Obergrussberger","year":"2014","journal-title":"Current Protocols in Pharmacology \/ Editorial Board, S.J. Enna (Editor-in-Chief) ... [et Al.]"},{"issue":"1","key":"10.1016\/j.vascn.2021.107125_bb0210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1124\/mol.116.103358","article-title":"Use-dependent block of human cardiac sodium channels by GS967","volume":"90","author":"Potet","year":"2016","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.vascn.2021.107125_bb0215","unstructured":"Recommended voltage protocols to study drug-cardiac ion channel interactions using recombinant cell lines. (n.d.). Retrieved February 5, 2020, from https:\/\/www.fda.gov\/media\/129686\/download."},{"issue":"6","key":"10.1016\/j.vascn.2021.107125_bb0220","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjp.0707492","article-title":"The cardiac persistent sodium current: An appealing therapeutic target?","volume":"153","author":"Saint","year":"2008","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.vascn.2021.107125_bb0225","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0022-3565(24)39107-4","article-title":"Comparison of L-type calcium channel blockade by nifedipine and\/or cadmium in guinea pig ventricular myocytes","volume":"294","author":"Shen","year":"2000","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"December","key":"10.1016\/j.vascn.2021.107125_bb0230","first-page":"81","article-title":"Voltage- and temperature-dependent allosteric modulation of \u03b17 nicotinic receptors by PNU120596","volume":"2","author":"Sitzia","year":"2011","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.vascn.2021.107125_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1027309703313","article-title":"Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel","volume":"254","author":"Stanat","year":"2003","journal-title":"Molecular and Cellular Biochemistry"},{"issue":"8","key":"10.1016\/j.vascn.2021.107125_bb0240","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/1087057111413924","article-title":"Automated patch clamp on mESC-derived cardiomyocytes for cardiotoxicity prediction","volume":"16","author":"Stoelzle","year":"2011","journal-title":"Journal of Biomolecular Screening\u202f: The Official Journal of the Society for Biomolecular Screening"},{"key":"10.1016\/j.vascn.2021.107125_bb0245","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fphar.2011.00076","article-title":"State-of-the-art automated patch clamp devices: Heat activation, action potentials, and high throughput in ion channel screening","volume":"2","author":"Stoelzle","year":"2011","journal-title":"Frontiers in Pharmacology"},{"issue":"2","key":"10.1016\/j.vascn.2021.107125_bb0250","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cpt.2137","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14\/S7B updates)","volume":"109","author":"Strauss","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"10.1016\/j.vascn.2021.107125_bb0255","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a fully integrated nonclinical\u2013clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective","volume":"109","author":"Vargas","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"11","key":"10.1016\/j.vascn.2021.107125_bb0260","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/j.1552-4604.1992.tb03797.x","article-title":"Classifying antiarrhythmic actions: By facts or speculation","volume":"32","author":"Vaughan Williams","year":"1992","journal-title":"Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1016\/j.vascn.2021.107125_bb0265","first-page":"207","article-title":"The inhibition of tamoxifen on sodium channel in SHG-44 glioma cell-line","volume":"25","author":"Wang","year":"2009","journal-title":"Chinese Journal of Applied Physiology"},{"issue":"6","key":"10.1016\/j.vascn.2021.107125_bb0270","article-title":"Comparison of gating properties and use-dependent block of Nav1.5 and Nav1.7 channels by anti-arrhythmics mexiletine and lidocaine","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vascn.2021.107125_bb0275","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1124\/jpet.105.094862","article-title":"An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts","volume":"316","author":"Wu","year":"2006","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.vascn.2021.107125_bb0280","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3389\/fphar.2019.01643","article-title":"Blinded in silico drug trial reveals the minimum set of ion channels for torsades de pointes risk assessment","volume":"10","author":"Zhou","year":"2020","journal-title":"Frontiers in Pharmacology"},{"issue":"7146","key":"10.1016\/j.vascn.2021.107125_bb0285","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nature05880","article-title":"Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures","volume":"447","author":"Zimmermann","year":"2007","journal-title":"Nature"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871921001787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871921001787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:05:09Z","timestamp":1761005109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871921001787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":56,"alternative-id":["S1056871921001787"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2021.107125","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reliable identification of cardiac conduction abnormalities in drug discovery using automated patch clamp II: Best practices for Nav1.5 peak current in a high throughput screening environment","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2021.107125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107125"}}